Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
Intravenous gemcitabine is the standard of care for patients with metastatic cancer of the pancreas. Gemcitabine-based chemotherapy combinations, either doublets or triplets, have been tested in the past but have offered a small advantage (Brodoefel et al. in Eur J Radiol 73:594–600, 2010). In the present study, we present the results of the triplet gemcitabine–oxaliplatin–erlotinib combination as firstline treatment in this setting.
Patients and methods
Seventy-one eligible patients were included in this study. All patients received chemotherapy with gemcitabine (1,100 mg/m2 on days 1 and 8) plus oxaliplatin (130 mg/m2 on day 8) and erlotinib (100 mg p.o./day for 21 days). The treatment cycle was 21 days.
Partial response was achieved in 15 patients (21 %; 95 % CI 11.63–30.62) and stable disease in 15 patients (21 %). Forty-one patients (57.8 %) experienced disease progression. Median progression-free survival was 5.2 months (range 0.6–34.7; 95 % CI 3.71–6.76). The median overall survival was 10.5 months (95 % CI 7.39–13.61) and the 1-year survival estimate 47.3 %. The main adverse events were grade 3/4 anemia occurring in three (4.2 %) patients and grade 3 and 4 thrombocytopenia occurring in eight (11.3 %) and three (4.2 %) patients, respectively. Grade 4 neutropenia was rare (1.4 %), and one patient presented febrile neutropenia.
This study demonstrated that the combination of gemcitabine, oxaliplatin and erlotinib is active, well tolerated and safe for patients with metastatic adenocarcinoma of the pancreas. However, the results do not seem to be better than those reported with chemotherapy alone.
KeywordsGemcitabine Oxaliplatin Erlotinib Phase II trial Pancreas
This work was partially supported by a research Grant from the Cretan Association for Biomedical Research (CABR). Dr E. K. was a recipient of a CABR clinical fellowship.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Malvezzi M, Bertuccio P, Levi F et al (2014) European cancer mortality predictions for the year 2014. Ann Oncol. doi: 10.1093/annonc/mdu138
- 10.Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778–3785PubMedCentralPubMedCrossRefGoogle Scholar
- 11.Kindler H, Niedzwiecki D, Hollis D et al (2007) A double-blind, placebo-controlled, randomised phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in pts with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. J Clin Oncol 25:18S (Abstact 4508)Google Scholar
- 12.Philip P, Benedetti J, Fenoglio-Preiser C et al (2007) Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study. J Clin Oncol 25:18S (Abstract LBA4509)Google Scholar
- 15.Patt YZ, Baron AD, Parks VA et al (2010) Phase II trial of gemcitabine (G), oxaliplatin (O), and erlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancers (BTC). J Clin Oncol 28:15s (Abstract 4153)Google Scholar
- 17.National Cancer Institute (2012) Common toxicity criteria for adverse events, version 2.0. National Cancer Institute, Bethesda. http://www.eortc.be/services/doc/ctc/ctcv20_4-30-992.pdf
- 21.Hu J, Zhao G, Wang HX et al (2011) A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 26:4–11Google Scholar
- 23.American Cancer Society (2014) Cancer facts & figures 2014. American Cancer Society, AtlandaGoogle Scholar
- 25.Van Cutsem E, Vervenne WL, Bennouna J (2009) Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. J Clin Oncol 27:15S (Abstract 4532)Google Scholar
- 26.Moore MJ, da Cunha Santos G, Kamel-Reid S et al (2007) The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3. J Clin Oncol 25:18S (Abstract 4521)Google Scholar